Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.
复制标题
DOI：
10.1016/j.vaccine.2018.02.065
复制
发表时间：
2018-03-27
期刊：
影响因子：
5.5
通讯作者：
Hotez PJ
中科院分区：
文献类型：
--
作者：
Nyon MP;Du L;Tseng CK;Seid CA;Pollet J;Naceanceno KS;Agrawal A;Algaissi A;Peng BH;Tai W;Jiang S;Bottazzi ME;Strych U;Hotez PJ
Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 2040 patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen-specific therapeutics nor approved vaccines are available. To address this need, we are developing a subunit recombinant protein vaccine comprising residues 377–588 of the MERS-CoV spike protein receptor-binding domain (RBD), which, when formulated with the AddaVax adjuvant, it induces a significant neutralizing antibody response and protection against MERS-CoV challenge in vaccinated animals. To prepare for the manufacture and first-in-human testing of the vaccine, we have developed a process to stably produce the recombinant MERS S377-588 protein in Chinese hamster ovary (CHO) cells. To accomplish this, we transfected an adherent dihydrofolate reductase-deficient CHO cell line (adCHO) with a plasmid encoding S377-588 fused with the human IgG Fc fragment (S377-588-Fc). We then demonstrated the interleukin-2 signal peptide-directed secretion of the recombinant protein into extracellular milieu. Using a gradually increasing methotrexate (MTX) concentration to 5 μM, we increased protein yield by a factor of 40. The adCHO-expressed S377-588-Fc recombinant protein demonstrated functionality and binding specificity identical to those of the protein from transiently transfected HEK293T cells. In addition, hCD26/dipeptidyl peptidase-4 (DPP4) transgenic mice vaccinated with AddaVax-adjuvanted S377-588-Fc could produce neutralizing antibodies against MERS-CoV and survived for at least 21 days after challenge with live MERS-CoV with no evidence of immunological toxicity or eosinophilic immune enhancement. To prepare for large scale-manufacture of the vaccine antigen, we have further developed a high-yield monoclonal suspension CHO cell line.
登录
查看更多内容
影响因子：
5.5
作者：
Konduru, Krishnamurthy;Bradfute, Steven B.;Jacques, Jerome;Manangeeswaran, Mohanraj;Nakamura, Siham;Morshed, Sufi;Wood, Steven C.;Bavari, Sina;Kaplan, Gerardo G.
通讯作者：
Kaplan, Gerardo G.
影响因子：
5.4
作者：
Du, Lanying;Zhao, Guangyu;Jiang, Shibo
通讯作者：
Jiang, Shibo
影响因子：
5.8
作者：
Du L;Yang Y;Zhou Y;Lu L;Li F;Jiang S
通讯作者：
Jiang S
影响因子：
7.8
作者：
Kobiyama K;Jounai N;Aoshi T;Tozuka M;Takeshita F;Coban C;Ishii KJ
通讯作者：
Ishii KJ
影响因子：
5.5
作者：
Ma, Cuiqing;Wang, Lili;Tao, Xinrong;Zhang, Naru;Yang, Yang;Tseng, Chien-Te K.;Li, Fang;Zhou, Yusen;Jiang, Shibo;Du, Lanying
通讯作者：
Du, Lanying